Sutro Biopharma (STRO) Assets Average (2018 - 2025)

Sutro Biopharma's Assets Average history runs 8 years deep, the most recent figure standing at $191.7 million for Q4 2025.

• In Q4 2025, Assets Average fell 54.29% year-over-year to $191.7 million; the TTM figure through Dec 2025 stood at $191.7 million (down 54.29% YoY), while the FY2025 annual figure was $280.5 million, down 34.61% from the prior year.
• Assets Average came in at $191.7 million for Q4 2025 at Sutro Biopharma, down from $236.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $470.4 million in Q3 2024 to a low of $191.7 million in Q4 2025.
• A 5-year average of $373.1 million and a median of $379.4 million in 2021 frame the typical range for Assets Average.
• Across the five-year window, Assets Average jumped 142.6% in 2021 and tumbled 54.29% in 2025, its largest moves.
• Sutro Biopharma's Assets Average stood at $356.4 million in 2021, then increased by 13.29% to $403.8 million in 2022, then climbed by 11.74% to $451.2 million in 2023, then slipped by 7.03% to $419.5 million in 2024, then sank by 54.29% to $191.7 million in 2025.
• According to Business Quant data, Assets Average over the past three periods registered $191.7 million, $236.0 million, and $291.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison